1997•Unpublished venueRequires access

Postoperative Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer

Hiromi Wada, Fumihiro Tanaka, Shigeki Hitomï

Open publisher page 0 citations

Abstract

Given that no therapeutic methods of postoperative adjuvant chemotherapy for non-small-cell lung cancer have been established, we selected UFT (tegafur and uracil) for investigation because UFT is less injurious to the host

About this research paper

What this paper is about

Given that no therapeutic methods of postoperative adjuvant chemotherapy for non-small-cell lung cancer have been established, we selected UFT (tegafur and uracil) for investigation because UFT is less injurious to the host

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Given that no therapeutic methods of postoperative adjuvant chemotherapy for non-small-cell lung cancer have been established, we selected UFT (tegafur and uracil) for investigation because UFT is less injurious to the host

Key concepts: Tegafur, Medicine, Chemotherapy, Adjuvant chemotherapy, Adjuvant, Lung cancer, Oncology, Internal medicine

Back to paper searchBrowse research topicsOriginal source
Postoperative Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer — Research Paper | ScholarLens